Clinical trial for OVA1 blood test showing promising results for detecting ovarian cancer

by Bob Yirka weblog

(Medical Xpress) -- Researchers at Vermillion, a medical diagnostics company have announced that clinical trials for its OVA1® blood test diagnostic tool have shown promising results. The tool, part of Vermillion’s OVA500 program is aimed at developing tests that provide doctors and patients with better information regarding whether ovarian growth’s (tumors) are cancerous or simply benign cysts, prior to surgery.

OVA1 was first approved for back in 2009, giving a hint as to why such tests tend to cost so much once they are finally approved. Lumps or tumors in ovaries are generally first discovered by manual manipulation of the pelvis by a doctor; unfortunately, the discovery doesn’t allow them to fully understand their nature without resorting to a biopsy. A that could reveal the type of tumor would save time, money and emotional stress for patients. If approved for use by doctors, OVA1 would allow a medical professional to take a small blood sample at the time that any unusual changes in the ovary are noticed. Testing involves using software analysis of the sample using proprietary algorithms developed by Vermillion, it performs calculations on five immunoassays and produces a number that indicates the likelihood of a tumor of being malignant. In the trials, which are conducted independent of Vermillion, 494 patients were involved in the most recent trial (a thousand have participated overall) with the focus on women already diagnosed with still in the early stages and those that are premenopausal. The premenopausal group was included in the study because few women in that group get that type of cancer but a lot of them get benign cysts.

Overall it appears OVA1 did quite well, finding a sensitivity of 94% for the premenopausal patients and 91% for those who were known to have early stage cancers. The percentages indicate the ability of the blood test to detect cancer (or rule it out) in the people tested. In addition, false positives were rated as very low (just 2%).

The announcement caused shares of Vermillion stock to rise significantly, but more importantly, suggests that the blood test works as advertised which means that someday soon, women may perhaps be spared the torment of undergoing a surgical procedure and then worse perhaps, waiting two or more days for the results, when all they actually have is a benign cyst.

More information: Press release

Related Stories

FDA clears biomarker test for ovarian cancer

date Sep 06, 2011

Approval last week by U.S. Food and Drug Administration (FDA) clears the path for nationwide use of tools that show the greatest specificity in estimating the risk of ovarian cancer in women with a pelvic mass.

U.S. panel rejects ovarian cancer screening

date Apr 10, 2012

(HealthDay) -- A leading U.S. government panel has renewed its 2004 recommendation that women at average risk for ovarian cancer not get screened for the disease.

Ultrasound may better classify ovarian tumors

date Nov 13, 2007

An elevated level of the protein CA-125 in blood is considered an indicator of whether an ovarian tumor is benign or malignant. This measure, however, can often be inaccurate. Another option is an ultrasound examination of ...

New blood test for early cancer detection developed

date Feb 21, 2012

A simple blood test is being developed by researchers at Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center in Beer-Sheva, Israel that may provide early detection of many types of cancer.

Recommended for you

Spicy treatment the answer to aggressive cancer?

date Jul 03, 2015

It has been treasured by food lovers for thousands of years for its rich golden colour, peppery flavour and mustardy aroma…and now turmeric may also have a role in fighting cancer.

Cancer survivors who smoke perceive less risk from tobacco

date Jul 02, 2015

Cancer survivors who smoke report fewer negative opinions about smoking, have more barriers to quitting, and are around other smokers more often than survivors who had quit before or after their diagnosis, according to a ...

Melanoma mutation rewires cell metabolism

date Jul 02, 2015

A mutation found in most melanomas rewires cancer cells' metabolism, making them dependent on a ketogenesis enzyme, researchers at Winship Cancer Institute of Emory University have discovered.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.